Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 in Schizophrenia with Negative Symptoms
NCT00922272Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing SPD489 Maintenance with Placebo Withdrawal (2 arms). Primary endpoints: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at 10 weeks and Change From Double-blind Randomization Baseline in SANS-18 Total Score at 4 weeks. Started Sep 2009; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00922272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922272.